20 Anderten et al found that, while the annual cost difference for DM-related prescriptions was lower in German patients with T2DM who persistently used insulin glargine compared with patients who switched insulin type, this failed to reach statistical significance. 13 Similarly, total treatment costs (DM-related prescriptions and other medical services) were lower but not significantly different between persistent and nonpersistent insulin glargine patients.
← all excerpts
Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review.
1
—
—